The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Inclusion Criteria:

• 18-65 years of age, inclusive
• primary diagnosis of chronic HCV infection
• non-responders to previous pegylated interferon-based therapy

Exclusion Criteria:

• patients naive to interferon-based therapy for chronic HCV infection